natgillin/translations-raw huggingface dataset:
While you take Envarsus your doctor also needs to know if you are taking potassium supplements or certain diuretics used for heart failure, hypertension and kidney disease (e.g. amiloride, triamterene, or spironolactone), nonsteroidal anti-inflammatory substances (NSAIDs, e.g. ibuprofen) used for fever, inflammation and pain, anticoagulants (blood thinners), or oral medicines for diabetes. 
Zdravnik mora tudi vedeti, če med jemanjem zdravila Envarsus jemljete dodatke kalija ali nekatere diuretike, ki se uporabljajo za preprečevanje srčne odpovedi, za zdravljenje hipertenzije in bolezni ledvic (npr. amilorid, triamteren ali spironolakton), nesteroidna protivnetna zdravila (npr. ibuprofen), ki se uporabljajo za zdravljenje povišane telesne temperature, vnetja in bolečin, antikoagulante
This medicinal product should only be prescribed, and changes in immunosuppressive therapy be initiated, by physicians experienced in immunosuppressive therapy and the management of transplant patients. 
Samo zdravniki, izkušeni v imunosupresivnem zdravljenju in vodenju bolnikov s presadki, smejo predpisovati to zdravilo in spreminjati imunosupresivno zdravljenje.
Envarsus 0.75 mg prolonged-release tablets are oval, white to off-white uncoated tablet, debossed with “0.75” on one side and “TCS” on the other side. 
Zdravilo Envarsus 0,75 mg tablete s podaljšanim sproščanjem so ovalne, bele do belkaste, neobložene tablete, z vtisom "0.75" na eni strani in "TCS" na drugi strani.
During the initial post-transplant period, monitoring of the following parameters should be undertaken on a routine basis: blood pressure, ECG, neurological and visual status, fasting blood glucose levels, electrolytes (particularly potassium), liver and renal function tests, haematology parameters, coagulation values, and plasma protein determinations. 
nevrološko stanje in stanje vida, koncentracijo glukoze na tešče, elektrolite (zlasti kalij), teste delovanja jeter in ledvic, hematološke parametre, koagulacijske vrednosti in koncentracijo beljakovin v plazmi.
Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. 
Preprečevanje zavrnitve presadka pri odraslih prejemnikih alogenskega presadka ledvic ali jeter.
A strong correlation exists between AUC and whole blood trough levels at steady-state for Envarsus. 
Med AUC in najnižjimi koncentracijami v polni krvi v stanju dinamičnega ravnovesja obstaja močna korelacija za zdravilo Envarsus.
Afterwards regular blood tests by your doctor will be required to define the correct dose and to adjust the dose from time to time. 
Redne krvne preiskave bodo potrebne tudi med nadaljevanjem zdravljenja zaradi preverjanja ustreznosti odmerka in morebitnega potrebnega prilagajanja.
Dose reduction may be necessary in patients with severe liver impairment in order to maintain the tacrolimus blood trough levels within the recommended target range. 
Za ohranitev najmanjše koncentracije takrolimusa v krvi znotraj priporočenega ciljnega območja bo morda pri bolnikih s hudo okvaro jeter potrebno zmanjšanje odmerka.
Musculoskeletal and connective tissue disorders arthralgia, back pain, muscle cramps, pain in limb joint disorders mobility decreased 
Bolezni mišično skeletnega sistema in vezivnega tkiva artralgija, bolečine v hrbtu, mišični krči, bolečine v okončini težave s sklepi zmanjšanje gibljivosti
Respiratory, thoracic and mediastinal disorders parenchymal lung disorders, dyspnoea, pleural effusion, cough, pharyngitis, nasal congestion and inflammations respiratory failures, respiratory tract disorders, asthma acute respiratory distress syndrome 
dispneja, plevralni izliv, kašelj, faringitis, zamašenost nosu in vnetja dihalna odpoved, bolezni dihal, astma akutni respiratorni distresni sindrom
Weaker interactions have been observed with clotrimazole, clarithromycin, josamycin, nifedipine, nicardipine, diltiazem, verapamil, amiodarone, danazol, ethinylestradiol, omeprazole and nefazodone. 
nifedipinom, nikardipinom, diltiazemom, verapamilom, amiodaronom, danazolom, etinilestradiolom, omeprazolom in nefazodonom.
The relationship between tacrolimus trough levels and systemic exposure (AUC0-24) is well correlated and is similar between the immediate-release formulation and Envarsus. 
Razmerje med najnižjimi koncentracijami takrolimusa in sistemsko izpostavljenostjo (AUC0-24) korelira in je za obe farmacevtski obliki s takojšnjim sproščanjem in za zdravilo Envarsus podobno.
In comparison to Caucasians, black patients may require higher tacrolimus doses to achieve similar trough levels. 
Rasa Pri bolnikih črne rase bodo za dosego enakih najnižjih koncentracij morda potrebni višji odmerki takrolimusa kot pri belcih.
Your doctor will usually reduce your Envarsus dose once your condition has stabilised. 
Ko se bo vaše stanje ustalilo, bo zdravnik odmerek zdravila Envarsus običajno zmanjšal.
Grapefruit juice has been reported to increase the blood level of tacrolimus and should, therefore, be avoided. 
Opisano je, da grenivkin sok zveča koncentracijo takrolimusa v krvi, zato se je treba pitju grenivkinega soka izogibati.
Patients receiving tacrolimus are frequently at increased risk for infections (viral, bacterial, fungal, protozoal). 
Infekcijske in parazitske bolezni Bolnike med zdravljenjem s takrolimusom pogosto bolj ogrožajo okužbe (virusne, bakterijske,
Cases of pure red cell aplasia (PRCA) have been reported in patients treated with tacrolimus. 
Čista aplazija rdečih krvnih celic Pri bolnikih, zdravljenih s takrolimusom, so poročali o primerih čiste aplazije rdečih krvnih celic
Magnesium stearate Tartaric acid (E334) Butylated hydroxytoluene (E321) Dimethicone 350 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi hipromeloza laktoza monohidrat makrogol 6000 poloksamer 188 magnezijev stearat vinska kislina (E334) butilirani hidroksitoluen (E321) dimetikon 350
Eye disorders eye disorders, vision blurred, photophobia cataract blindness optic neuropathy 
zamegljen vid, fotofobija katarakta slepota nevropatija vidnega živca
Envarsus 0.75 mg prolonged-release tablets Envarsus 1 mg prolonged-release tablets Envarsus 4 mg prolonged-release tablets 
Envarsus 0,75 mg tablete s podaljšanim sproščanjem Envarsus 1 mg tablete s podaljšanim sproščanjem Envarsus 4 mg tablete s podaljšanim sproščanjem
These infections are often related to a high total immunosuppressive burden and may lead to serious or fatal conditions that physicians should consider in the differential diagnosis in immunosuppressed patients with deteriorating hepatic or renal function or neurological symptoms. 
Ti dve okužbi sta pogosto povezani z visokim imunosupresivnim bremenom in lahko vodita v resna ali smrtna stanja.
Skin and subcutaneous tissue disorders rash, pruritus, alopecias, acne, sweating increased dermatitis, photosensitivity toxic epidermal necrolysis (Lyell's syndrome) 
močnejše znojenje dermatitis, fotosenzibilnost toksična epidermalna nekroliza (Lyellov sindrom)
As tacrolimus treatment may be associated with hyperkalaemia, or may increase pre-existing hyperkalaemia, high potassium intake, or potassium-sparing diuretics (e.g. amiloride, triamterene, or spironolactone) should be avoided (see section 4.4). 
Zato se je treba izogibati uživanju večjih količin kalija in uporabi diuretikov, ki varčujejo s kalijem (npr. amilorid, triamteren ali spironolakton) (glejte poglavje 4.4).
increased uric acid or lipids in the blood, decreased appetite, loss of appetite, increased acidity of the blood, other changes in the blood salts (seen in blood tests) - anxiety symptoms, confusion and disorientation, depression, mood changes, nightmare, 
- znižanje vrednosti magnezija, fosfatov, kalija, kalcija ali natrija v krvi, preobremenitev s tekočino, zvišanje vrednosti sečne kisline ali lipidov v krvi, zmanjšanje apetita, izguba apetita, zvečana kislost krvi, druge spremembe elektrolitov v krvi (vidno na krvnih preiskavah) - simptomi tesnobe, zmedenost in dezorientiranost, depresija, razpoloženjske spremembe, nočne more, halucinacije, duševne motnje
Benign and malignant tumours have been reported following Envarsus treatment. 
Po zdravljenju z zdravilom Envarsus so poročali o pojavu benignih in malignih tumorjev.
High potassium intake or potassium-sparing diuretics should be avoided (see section 4.5). 
Uživanju obilice kalija in uporabi diuretikov, ki varčujejo s kalijem, se je treba izogniti (glejte poglavje 4.5).
Symptoms have included tremor, headache, nausea and vomiting, infections, urticaria, lethargy and increases in blood urea nitrogen, serum creatinine and alanine aminotransferase levels. 
urtikarija, letargija, zvišanje dušika iz sečnine v krvi, povečanje koncentracije kreatinina v serumu in zvišanje ravni alanin-aminotransferaze.
Blood and lymphatic system disorders anaemia, thrombocytopenia, leukopenia, red blood cell analyses abnormal, leukocytosis coagulopathies, pancytopenia, neutropenia, coagulation and bleeding analyses, abnormal thrombotic thrombocytopenic purpura, hypoprothrombinaemia, thrombotic microangiopathy pure red cell aplasia, agranulocytosis, haemolytic anaemia 
Bolezni krvi in limfatičnega sistema anemija, trombocitopenija, levkopenija, nenormalnosti pri analizi eritrocitov, levkocitoza koagulopatije, pancitopenija, nevtropenija, nenormalnosti pri analizah koagulacije in krvavitev trombotična trombocitope nična purpura,
Tell your doctor if you are taking or need to take ibuprofen (used to treat fever, inflammation and pain), amphotericin B (used to treat fungal infections), antibiotics (used to treat bacterial infections, e.g. aminoglycosides, vancomycin or clotrimazole) or antivirals (used to treat viral infections, e.g. aciclovir). 
Obvestite zdravnika, če jemljete ali bi morali jemati ibuprofen (uporablja se za zdravljenje povišane telesne temperature, vnetja in bolečine), amfotericin B (uporablja se za zdravljenje glivičnih okužb),
abdominal pain, indigestion, constipation, passing wind, bloating, loose stools - bile duct disorders, yellowing of the skin due to liver problems, liver tissue damage and inflammation of the liver - itching, rash, hair loss, acne, increased sweating - pain in joints, limbs or back, muscle cramps - insufficient function of the kidneys, reduced production of urine, impaired or painful urination - general weakness, fever, collection of fluid in your body, pain and discomfort, increase of the enzyme alkaline phosphatase in your blood, weight gain, feeling of temperature disturbed - insufficient function of your transplanted organ 
- srbenje, izpadanje las, akne, čezmerno znojenje - bolečine v sklepih, udih ali hrbtu, mišični krči - nezadostno delovanje ledvic, zmanjšano nastajanje seča, oslabljeno ali boleče uriniranje - splošna oslabelost, zvišana telesna temperatura, kopičenje tekočine v telesu, bolečine in nelagodje, zvišanje alkalne fosfataze v krvi, povečanje telesne mase, moteno zaznavanje telesne temperature - nezadostno delovanje presajenega organa
CYP3A4 inhibitors potentially leading to increased tacrolimus blood levels Clinically, the following substances have been shown to increase tacrolimus blood levels: Strong interactions have been observed with antifungal agents such as ketoconazole, fluconazole, itraconazole, voriconazole and isavuconazole, the macrolide antibiotic erythromycin, HIV protease inhibitors (e.g. ritonavir, nelfinavir, saquinavir) or Hepatitis C Virus (HCV) protease inhibitors (e.g. telaprevir, boceprevir, and the combination of ombitasvir and paritaprevir with ritonavir, when used with and without dasabuvir), the pharmacokinetic enhancer cobicistat, and the tyrosine kinase inhibitors nilotinib and imatinib. 
Močne interakcije so opazili z antimikotiki, kot so ketokonazol, flukonazol, itrakonazol, vorikonazol in izavukonazol, makrolidnim antibiotikom eritromicinom, zaviralci proteaz HIV (npr. ritonavir, nelfinavir, sakvinavir) ali zaviralci proteaze virusa hepatitisa C (HCV) (npr. telaprevir, bokeprevir in kombinacijo ombitasvirja in paritaprevirja z ritonavirjem, z dasabuvirjem ali brez njega), s farmakokinetičnim stopnjevalcem kobicistatom in zaviralcema tirozin-kinaze nilotinibom ter imatinibom.
Therapeutic drug monitoring of mycophenolic acid may be appropriate when switching from ciclosporin to tacrolimus or vice versa. 
V primeru prehoda s ciklosporina na takrolimus ali obratno je lahko ustrezno terapevtsko spremljanje mikofenolne kisline.
Benign as well as malignant neoplasms including EBV-associated lymphoproliferative disorders and skin malignancies have been reported in association with tacrolimus treatment. 
V povezavi z zdravljenjem s takrolimusom so poročali o benignih in malignih neoplazmah, vključno z limfoproliferativnimi boleznimi, povezanimi z EBV in kožnimi malignomi.
Eye disorders, sometimes progressing to loss of vision, have been reported in patients treated with tacrolimus. 
Pri bolnikih, zdravljenih s takrolimusom, so poročali o očesnih motnjah, ki so včasih napredovale do izgube vida.
Oval, white to off-white uncoated tablet, debossed with “0.75” on one side and “TCS” on the other side. 
Ovalna, bela do belkasta, neobložena tableta, z vtisom "0.75" na eni strani in "TCS" na drugi strani.
- medicines known as “statins”, used to treat elevated cholesterol and triglycerides - phenytoin or phenobarbital, used to treat epilepsy - prednisolone and methylprednisolone, belonging to the class of corticosteroids and used to treat inflammations or suppress the immune system (e.g. in transplant rejection) - carbamazepine, used to prevent and control seizures - metamizole, used to treat pain and high fever - nefazodone, used to treat depression - herbal preparations containing St. John's Wort (Hypericum perforatum) 
- antiaritmiki (npr. amiodaron), ki se uporabljajo za obvladovanje aritmij (neenakomerno bitje srca) - zdravila, ki so znana kot "statini" in se uporabljajo pri zdravljenju zvišanega holesterola in trigliceridov - fenitoin ali fenobarbital, ki se uporabljata za zdravljenje epilepsije - prednizolon in metilprednizolon, ki spadata med kortikosteroide in se uporabljata za zdravljenje vnetij ali zaviranje imunskega sistema (npr. pri zavrnitvi presadka)
Tacrolimus blood trough levels should be determined approximately 24 hours post-dosing of Envarsus, just prior to the next dose. 
Vzorce za določitev najmanjše koncentracije takrolimusa je treba vzeti približno 24 ur po uporabi zdravila
The FKBP12-tacrolimus complex specifically and competitively binds to and inhibits calcineurin, leading to a calcium-dependent inhibition of T-cell signal transduction pathways, thereby preventing transcription of a discrete set of cytokine genes. 
Kompleks FKBP12-takrolimus se specifično in kompetitivno veže na kalcinevrin in ga zavre.
Do not drive or use any tools or machines if you feel dizzy or sleepy, or have problems seeing clearly after taking Envarsus. 
Če ste po uporabi zdravila Envarsus omotični ali zaspani ali imate zamegljen vid, ne smete voziti vozil ali upravljati z orodji ali stroji.
Please contact your doctor immediately, should you experience severe effects. 
Nemudoma obvestite zdravnika, če se vam med zdravljenjem pojavijo:
There is limited experience in non-Caucasian patients and patients at elevated immunological risk (e.g. retransplantation, evidence of panel reactive antibodies, PRA). 
Pri bolnikih, ki niso bele rase in bolnikih z večjim imunološkim tveganjem (npr. retransplantacija,
Other factors observed to increase the risk of these clinical conditions included pre-existing heart disease, corticosteroid usage, hypertension, renal or hepatic dysfunction, infections, fluid overload and oedema. 
so obstoječa bolezen srca, jemanje kortikosteroidov, hipertenzija, moteno delovanje ledvic ali jeter, okužbe, preobremenitev s tekočino in edemi.
These may worsen kidney or nervous system problems when taken together with Envarsus. 
Če se ta zdravila jemlje skupaj z zdravilom Envarsus, lahko poslabšajo težave z ledvicami ali živčevjem.
Each prolonged-release tablet contains 0.75 mg tacrolimus (as monohydrate). 
Ena tableta s podaljšanim sproščanjem vsebuje 0,75 mg takrolimusa (v obliki monohidrata).
The efficacy failure rate as measured by the composite endpoint of death, graft loss, centrally read BPAR and loss to follow-up was 18.3% in the Envarsus group and 19.6% in the Prograf group. 
centralno določena BPAR in bolnikov, izgubljenim za spremljanje, je bila 18,3 % za skupino z zdravilom Envarsus in 19,6 % za skupino z zdravilom Prograf.
Conversion of Prograf- or Advagraf-treated patients to Envarsus - allograft transplant patients Envarsus is not interchangeable with other existing tacrolimus containing medicinal products (immediate-release or prolonged-release) on an equal dose by dose basis. 
Zdravilo Envarsus ni zamenljivo z drugimi obstoječimi zdravili, ki vsebujejo takrolimus (takojšnje sproščanje ali podaljšano sproščanje) na osnovi enakega odmerka.
Envarsus 0.75 mg prolonged-release tablets Each prolonged-release tablet contains 0.75 mg tacrolimus (as monohydrate). 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Envarsus 0,75 mg tablete s podaljšanim sproščanjem Ena tableta s podaljšanim sproščanjem vsebuje 0,75 mg takrolimusa (v obliki monohidrata).
Only one of these has been shown in vitro to have immunosuppressive activity similar to that of tacrolimus. 
da deluje podobno imunosupresivno kot takrolimus.
Envarsus 4 mg prolonged-release tablets are oval, white to off-white uncoated tablet, debossed with “4” on one side and “TCS” on the other side. 
Zdravilo Envarsus 4 mg tablete s podaljšanim sproščanjem so ovalne, bele do belkaste, neobložene tablete, z vtisom "4" na eni strani in "TCS" na drugi strani.
Envarsus 1 mg prolonged-release tablets are oval, white to off-white uncoated tablet, debossed with “1” on one side and “TCS” on the other side 
Zdravilo Envarsus 1 mg tablete s podaljšanim sproščanjem so ovalne, bele do belkaste, neobložene tablete, z vtisom "1" na eni strani in "TCS" na drugi strani.
Investigations liver function tests abnormal blood alkaline phosphatase increased, weight increased amylase increased, ECG abnormal, heart rate and pulse investigations abnormal, weight decreased, blood lactate dehydrogenase increased echocardiogram abnormal, 
povečanje telesne mase zvišanje amilaze, nepravilnosti na EKG, nenormalna srčna frekvenca in ritem, zmanjšanje telesne mase, zvišanje laktatdehidrogenaze v krvi ehokardiografske nepravilnosti
In clinical studies in kidney transplant patients receiving Envarsus, the most frequent adverse reactions (at least in 2% of patients) were tremor, diabetes mellitus, blood creatinine increased, urinary tract infection, hypertension, BK virus infection, renal impairment, diarrhoea, toxicity to various agents, and toxic nephropathy all of which are known to occur in the respective patient population under immunosuppressive treatment. 
zvišanje kreatinina v krvi, okužbe sečil, hipertenzija, okužba z virusom BK, okvara ledvic, driska, toksičnost na različne učinkovine in toksična nefropatija, za katere je znano, da se pri imunosupresivnem zdravljenju pojavljajo pri zadevni populaciji bolnikov.
Envarsus contains lactose. 
Zdravilo Envarsus vsebuje laktozo.
Vascular disorders hypertension thromboembolic and ischaemic events, vascular hypotensive disorders, haemorrhage, peripheral vascular disorders venous thrombosis deep limb, shock, infarction 
žilne hipotenzivne motnje, krvavitev, bolezen perifernih žil globoka venska tromboza v udih, šok, infarkt
Common side effects (may affect up to 1 in 10 people): - reduction in blood cell counts (platelets, red or white blood cells), increase in white blood cell counts, changes in red blood cell counts (seen in blood tests) - reduced magnesium, phosphate, potassium, calcium or sodium in the blood, fluid overload, 
Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov): - zmanjšanje števila krvnih celic (trombocitov in rdečih ali belih krvnih celic), povečanje števila belih krvnih celic, spremembe v številu rdečih krvnih celic (vidno na krvnih preiskavah)
Higher Cavg (~50%), reduced peak trough fluctuation (Cmax/Cmin) and a longer Tmax were seen for Envarsus when compared with both, tacrolimus immediate-release formulation (Prograf) and a tacrolimus once daily formulation (Advagraf). 
(Cmax/Cmin) in daljši Tmax tako v primerjavi s takrolimusom s farmacevtsko obliko s takojšnjim sproščanjem (zdravilo Prograf) kot s takrolimusom s farmacevtsko obliko enkrat na dan (zdravilo
A negative effect of tacrolimus on male fertility in the form of reduced sperm count and motility was observed in rats. 
Pri podganah so opažali negativen vpliv takrolimusa na moško plodnost; kazal se je z zmanjšanjem števila in gibljivosti semenčic.
Envarsus 0.75 mg prolonged-release tablets tacrolimus 
Envarsus 0,75 mg tablete s podaljšanim sproščanjem tacrolimus
Envarsus 0.75 mg prolonged-release tablets 
Envarsus 0,75 mg tablete s podaljšanim sproščanjem
Each prolonged-release tablet contains 4 mg tacrolimus (as monohydrate). 
Ena tableta s podaljšanim sproščanjem vsebuje 4 mg takrolimusa (v obliki monohidrata).
Hepatobiliary disorders bile duct disorders, hepatocellular damage and hepatitis, cholestasis and jaundice venoocclusive liver disease, hepatic artery thrombosis hepatic failure 
okvara jetrnih celic in hepatitis, holestaza in zlatenica venookluzivna bolezen jeter, tromboza jetrne arterije odpoved jeter
Envarsus 4 mg prolonged-release tablets Each prolonged-release tablet contains 4 mg tacrolimus (as monohydrate). 
Envarsus 4 mg tablete s podaljšanim sproščanjem Ena tableta s podaljšanim sproščanjem vsebuje 4 mg takrolimusa (v obliki monohidrata).
Uncommon side effects (may affect up to 1 in 100 people): - changes in blood clotting, reduction in the number of all types of blood cells (seen in blood tests) - dehydration, inability to urinate - psychotic behaviour, such as delusions, hallucinations, and confusion - abnormal blood test results: reduced protein or sugar, increased phosphate, increase of the enzyme lactate dehydrogenase - coma, bleeding in the brain, stroke, paralysis, brain disorder, speech and language abnormalities, memory problems - clouding of the eye lens, partial or total inability to hear - irregular heartbeat, stop of heartbeat, reduced performance of your heart, disorder of the heart muscle, enlargement of the heart muscle, stronger heartbeat, abnormal ECG, heart rate and pulse abnormal - blood clot in a vein of a limb, shock - difficulties in breathing, respiratory tract disorders, asthma - acute or chronic inflammation of the pancreas, inflammation of the lining of the inner wall of the abdomen, obstruction of the gut, increased blood level of the enzyme amylase, reflux of stomach contents in your throat, delayed emptying of the stomach - inflammation of the skin, burning sensation in the sunlight - joint disorders - painful menstruation and abnormal menstrual bleeding - multiple organ failure, flu-like illness, increased sensitivity to heat and cold, feeling of pressure on your chest, jittery or abnormal feeling, weight loss 
- motnje strjevanja krvi, zmanjšanje števila vseh krvnih celic (vidno na krvnih preiskavah) - dehidracija, nezmožnost uriniranja - psihotično vedenje, kot so prividi, halucinacije in zmedenost - nenormalni rezultati krvnih preiskav: zmanjšanje beljakovin ali sladkorja v krvi, zvišanje fosfatov, zvišanje encima laktat-dehidrogenaze - koma, možganske krvavitve, možganska kap, paraliza, možganska motnja, motnje govora in izražanja, težave s spominom - motnost očesnih leč, delna ali popolna gluhost
Oval, white to off-white uncoated tablet, debossed with “1” on one side and “TCS” on the other side. 
Ovalna, bela do belkasta, neobložena tableta, z vtisom "1" na eni strani in "TCS" na drugi strani.
fever, nausea or vomiting - an infection, leading to problems with your kidney or neurological symptoms - headache, altered mental status, seizures and visual disturbances - weakness, change in skin or eye colour, easy bruising, infection, cough, anaemia 
- glavobol, spremenjeno duševno stanje, krči in motnje vida, - oslabelost, sprememba barve kože ali oči, nagnjenost k podplutbam, okužba, kašelj, anemija.
Oval, white to off-white uncoated tablet, debossed with “4” on one side and “TCS” on the other side. 
Ovalna, bela do belkasta, neobložena tableta, z vtisom "4" na eni strani in "TCS" na drugi strani.